SAGE Therapeutics (SAGE) Price & Analysis

Compare

940 Followers

SAGE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.62 - $9.36

Previous CloseN/A

Volume244.47K

Average Volume (3M)3.20M

Market Cap

$543.61M

Enterprise Value$216.86M

Total Cash (Recent Filing)$365.57M

Total Debt (Recent Filing)$11.42M

Price to Earnings (P/E)―

Beta1.61

Next Earnings

Nov 11, 2025

EPS Estimate

-0.74

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.79

Shares Outstanding51,654,000

10 Day Avg. Volume5,839,790

30 Day Avg. Volume3,198,592

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.40

Enterprise Value/Revenue3.08

Enterprise Value/Gross Profit3.45

Enterprise Value/Ebitda-0.72

Forecast

1Y Price Target

$8.60

Price Target Upside-0.92% Downside

Rating ConsensusHold

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Acquisition StrategyThe transaction by Supernus is seen as logical since the company can leverage its marketed portfolio of several central nervous system products.

Cost SynergiesSupernus believes the transaction can be accretive in the future and could lead to $200mn in annual cost synergies.

Shareholder ValueThe $12/share maximum potential offer price represents a 74% premium to Sage's closing price.

Bears Say

Competitive LandscapeA deal with Supernus was unexpected, and leaves open the door for additional competition.

Market PresenceSUPN does not currently hold a presence in the women's health space, potentially challenging the expansion of SAGE's PPD product.

Revenue ChallengesCurrent revenue estimates for SAGE fall below the targets needed to achieve CVR payouts, indicating potential challenges ahead.

SAGE Therapeutics News

Supernus completes acquisition of Sage Therapeutics

Supernus (SUPN) Pharmaceuticals has completed its previously announced acquisition of Sage Therapeutics (SAGE). “Sage is an ideal fit...

8d ago

SAGE

SUPN

Sage Therapeutics reports Q2 EPS (79c), consensus (94c)

Reports Q2 revenue $31.7M, consensus $16.7M. Cash, cash equivalents and marketable securities as of June 30, 2025 were...

9d ago

SAGE

Supernus announces expiration of HSR waiting period for Sage Therapeutics

Supernus Pharmaceuticals (SUPN) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...

11d ago

SAGE

SUPN

SAGE Therapeutics Announces Nasdaq Delisting After Merger

SAGE Therapeutics ( ($SAGE) ) has shared an update. On July 30, 2025, SAGE Therapeutics, a company involved...

8d ago

SAGE

Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank

Scotiabank analyst George Farmer downgraded Sage Therapeutics (SAGE) to Sector Perform from Outperform with a $9.20 price target...

1M ago

SAGE

Sage Therapeutics cutting over 330 jobs, Boston Globe reports

Sage Therapeutics (SAGE) is laying off most of its employees after announcing its planned acquisition earlier this month,...

1M ago

SAGE

SUPN

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm’s price target on Sage Therapeutics (SAGE) to $8.50 from $11 and...

2M ago

SAGE

Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($RNA) ), ( ($BBIO) ), ( ($COTY) ), ( ($SAGE)...

2M ago

RNA

ALKS

Sage Therapeutics price target raised to $9 from $7 at Baird

Baird analyst Joel Beatty raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $7 and...

2M ago

SAGE

H.C. Wainwright sees potential competition for Sage from Biogen

H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise,...

2M ago

BIIB

SAGE

Sage Therapeutics price target raised to $9 from $8 at Truist

Truist analyst Joon Lee raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $8 and...

2M ago

SAGE

SUPN

Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments

Canaccord Genuity analyst Sumant Kulkarni has maintained their neutral stance on SAGE stock, giving a Hold rating today....

2M ago

SAGE

Sage Therapeutics price target raised to $8.50 from $8 at Canaccord

Canaccord raised the firm’s price target on Sage Therapeutics (SAGE) to $8.50 from $8 and keeps a Hold...

2M ago

BIIB

SAGE

Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and...

2M ago

SAGE

SAGE FAQ

What was SAGE Therapeutics, Inc. (US)’s price range in the past 12 months?

SAGE Therapeutics, Inc. (US) lowest stock price was $4.62 and its highest was $9.36 in the past 12 months.

What is SAGE Therapeutics, Inc. (US)’s market cap?

SAGE Therapeutics, Inc. (US)’s market cap is $543.61M.

When is SAGE Therapeutics, Inc. (US)’s upcoming earnings report date?

SAGE Therapeutics, Inc. (US)’s upcoming earnings report date is Nov 11, 2025 which is in 95 days.

How were SAGE Therapeutics, Inc. (US)’s earnings last quarter?

SAGE Therapeutics, Inc. (US) released its earnings results on Jul 29, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.942 by $0.152.

Is SAGE Therapeutics, Inc. (US) overvalued?

According to Wall Street analysts SAGE Therapeutics, Inc. (US)’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SAGE Therapeutics, Inc. (US) pay dividends?

SAGE Therapeutics, Inc. (US) does not currently pay dividends.

What is SAGE Therapeutics, Inc. (US)’s EPS estimate?

SAGE Therapeutics, Inc. (US)’s EPS estimate is -0.74.

How many shares outstanding does SAGE Therapeutics, Inc. (US) have?

SAGE Therapeutics, Inc. (US) has 51,654,000 shares outstanding.

What happened to SAGE Therapeutics, Inc. (US)’s price movement after its last earnings report?

SAGE Therapeutics, Inc. (US) reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.942. Following the earnings report the stock price went down -0.23%.

Which hedge fund is a major shareholder of SAGE Therapeutics, Inc. (US)?

Currently, no hedge funds are holding shares in SAGE

SAGE Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-60.43%

Trailing 12-Months

Asset Growth

-39.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SAGE Therapeutics, Inc. (US)

SAGE Therapeutics (SAGE) is a biopharmaceutical company committed to developing novel therapies for central nervous system (CNS) disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, SAGE focuses on identifying and developing medicines that target the brain's neurotransmitter pathways to address conditions such as depression, insomnia, and other CNS-related diseases. The company's flagship products include Zulresso (brexanolone) for the treatment of postpartum depression and other promising compounds in its pipeline aimed at various psychiatric and neurological conditions.

SAGE Therapeutics (SAGE) Earnings & Revenues

Historic Earnings Reports

SAGE Company Deck

SAGE Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook with strong growth and milestones achieved for ZURZUVAE, a significant reduction in R&D expenses, and a clear focus on pipeline opportunities. However, there remains uncertainty with ongoing strategic alternatives and continued net losses, albeit reduced.View all SAGE earnings summaries

SAGE Stock 12 Month Forecast

Average Price Target

$8.60

▼(-0.92% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","6.25":"$6.25","8.5":"$8.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.25,8.5,10.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.08,9.304615384615385,9.52923076923077,9.753846153846155,9.978461538461538,10.203076923076923,10.427692307692308,10.652307692307692,10.876923076923077,11.10153846153846,11.326153846153847,11.55076923076923,11.775384615384615,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.08,9.043076923076923,9.006153846153847,8.96923076923077,8.932307692307692,8.895384615384616,8.858461538461539,8.821538461538461,8.784615384615384,8.747692307692308,8.71076923076923,8.673846153846153,8.636923076923077,{"y":8.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.08,8.766153846153847,8.452307692307693,8.138461538461538,7.8246153846153845,7.510769230769231,7.196923076923078,6.883076923076923,6.569230769230769,6.2553846153846155,5.941538461538462,5.627692307692308,5.313846153846154,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.11,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.08,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >